Leiner Loratadine Success In 2004 Positions Firm For Further OTC Growth
This article was originally published in The Tan Sheet
Executive Summary
Leiner views its OTC sales growth during its first fiscal quarter as representative of the way the company is reshaping its current business strategy to focus more on nonprescription drugs
You may also be interested in...
Perrigo Moves In On Major Generic Firms With Agis Acquisition
Perrigo's acquisition of Israeli generic drug firm Agis Pharmaceuticals will put the combined entity's annualized sales over the $1 bil. mark and in the same league with major Rx generic drug players
Leiner Looks To Rule Claritin Equivalent Market With Summer Launches
Leiner Health Products will seek to control the store brand loratadine market with late summer launches of equivalents to Schering-Plough's Claritin RediTabs and D-24
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC